Kyntra Bio, Inc. (KYNB NASDAQ) stock market data APIs
$8.0028
0.2(2.5%)
as of September 11, 2026
Try our APIs with
free plan!
Kyntra Bio, Inc. Financial Data Overview
Price chart is built with
Anychart
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Prev. Close
8.0028
Open
8.2004
High
8.2083
Low
7.9082
52 wk Range
6.32-12.58
Market Cap
32 272 K
Shares Outstanding
4 049 K
Revenue
4 616 K
EPS
-4.68
Beta
1.064
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kyntra Bio, Inc. data using free add-ons & libraries
Get Kyntra Bio, Inc. Fundamental Data
Kyntra Bio, Inc. Fundamental data includes:
- Net Revenue: 4 616 K
- EBITDA: -50 035 000
- Earnings Per Share: -7
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-13
- EPS/Forecast: -3.18
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kyntra Bio, Inc. News
New
FibroGen Q2 2026 Earnings Preview
* FibroGen (KYNB [https://seekingalpha.com/symbol/KYNB]) is scheduled to announce Q2 earnings results on Thursday, August 13th, after market close. * The consensus EPS estimate is -$3.18, [https:/...
Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates
Vericel Corporation (VCEL) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to a loss of $0.01 per share a year ago...
NovoCure (NVCR) Reports Q2 Loss, Beats Revenue Estimates
NovoCure (NVCR) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.36 per share a year ago. These figures are adjust...
Kyntra Bio targets Q4 2026 interim readout while extending cash runway into 2028
Earnings Call Insights: Kyntra Bio (KYNB) Q1 2026 MANAGEMENT VIEW * CEO Thane Wettig said the quarter’s focus remained on “consistent progress we have made across our portfolio,” highlightin...
Get Kyntra Bio, Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
